摘要
目的观察扶正解毒方联合多西他赛加奈达铂方案治疗晚期非小细胞肺癌临床疗效和毒副反应。方法 76例晚期非小细胞肺癌(NSCLC)随机分为治疗组和对照组,各38例,治疗组采用扶正解毒方联合多西他赛加奈达铂化疗方案,对照组采用多西他赛加奈达铂化疗方案,21d为一周期。结果治疗组有效率为52.63%,对照组为44.74%,两组比较无明显统计学意义(P>0.05);骨髓抑制、胃肠道反应治疗组均明显低于对照组,两组有明显统计学意义(P<0.05);治疗组在生活质量(KPS)评分及细胞免疫功能均显著高于对照组,两组比较有明显统计学意义(P<0.05)。结论扶正解毒方联合多西他赛加奈达铂治疗晚期非小细胞肺癌(NSCLC)疗效确切,明显减轻化疗毒副反应,增强免疫功能,提高患者生存质量,延长生存期。
Objective To observe the righting detoxification prescription combined docetaxel Saijianaida platinum in the treatment of advanced non-small cell lung cancer clinical efficacy and toxicity.Methods 76 patients with advanced non-small cell lung cancer（NSCLC） were randomly divided into treatment group and control group,the 38 cases,the treatment group were righting Jiedu United docetaxel Saijianaida platinum chemotherapy in the control group received docetaxel Saijianaida platinum chemotherapy and 21 days for a cycle.Results of the treatment group was 52.63%,44.74% in control group showed no statistically significant（P0.05）;bone marrow suppression,gastrointestinal reactions treatment group were significantly lower than the control group,two groups was statistically significant significance（P0.05）;treatment groups in quality of life（KPS） score and cellular immune function were significantly higher in the two groups are statistically significant（P0.05）.Conclusion Fuzheng Jiedu Saijianaida Platinum Joint docetaxel in treatment of advanced non-small cell lung cancer（NSCLC） is effective,significantly reduce the toxicity of chemotherapy,enhancing immune function,improve patient quality of life and prolong survival.
出处
《中国中医药现代远程教育》
2011年第5期152-153,共2页
Chinese Medicine Modern Distance Education of China
